Clinical Trials Directory

Trials / Unknown

UnknownNCT02485184

TIPS vs Endoscopic Therapy for Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis

TIPS Versus Endoscopic Therapy for the Prevention of Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis: A Randomized Controlled Trial

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
120 (estimated)
Sponsor
Air Force Military Medical University, China · Academic / Other
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

portal vein thrombosis may be a negative prognostic marker of variceal bleeding in liver cirrhosis. Compared with conventional endoscopic and pharmacological therapy, transjugular intrahepatic portosystemic shunt may further improve the outcomes of portal vein thrombosis in liver cirrhosis with variceal bleeding.

Detailed description

Portal vein thrombosis may be a negative prognostic marker of variceal bleeding in liver cirrhosis. Compared with conventional endoscopic and pharmacological therapy, transjugular intrahepatic portosystemic shunt may further improve the outcomes of portal vein thrombosis in liver cirrhosis with variceal bleeding. However, the safety of transjugular intrahepatic portosystemic shunt remains uncertain in patients with portal vein thrombosis.

Conditions

Interventions

TypeNameDescription
PROCEDURETransjugular intrahepatic portosystemic shuntTransjugular intrahepatic portosystemic shunt refers to an interventional radiological procedure by placing a stent between portal vein and hepatic vein. No specific device was used in the Interventional field.
DRUGNon-selective beta blockersNon-selective beta blockers are the drugs for reducing the portal pressure.
PROCEDUREEndoscopic therapyEndoscopic therapy includes the endoscopic variceal band ligation
DRUGAnticoagulationAnticoagulation therapy includes heparin and warfarin.

Timeline

Start date
2017-07-09
Primary completion
2024-12-31
Completion
2024-12-31
First posted
2015-06-30
Last updated
2022-10-25

Locations

8 sites across 1 country: China

Source: ClinicalTrials.gov record NCT02485184. Inclusion in this directory is not an endorsement.